JPS621372B2 - - Google Patents
Info
- Publication number
- JPS621372B2 JPS621372B2 JP54116910A JP11691079A JPS621372B2 JP S621372 B2 JPS621372 B2 JP S621372B2 JP 54116910 A JP54116910 A JP 54116910A JP 11691079 A JP11691079 A JP 11691079A JP S621372 B2 JPS621372 B2 JP S621372B2
- Authority
- JP
- Japan
- Prior art keywords
- mice
- prosapogenin
- stress
- sart
- acetylcholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 206010042209 Stress Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 11
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 8
- 229960004373 acetylcholine Drugs 0.000 description 8
- 230000008602 contraction Effects 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 240000004371 Panax ginseng Species 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- YDQIRODFTJGGMP-UHFFFAOYSA-N Prosapogenin Chemical compound C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC34)C)(CO)C1=CCC2C3(C)CC(O)C(O)C4(C)C(=O)OC1OC(CO)C(O)C(O)C1O YDQIRODFTJGGMP-UHFFFAOYSA-N 0.000 description 3
- ZNFRITHWVZXJRK-UHFFFAOYSA-N Vitalboside A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O ZNFRITHWVZXJRK-UHFFFAOYSA-N 0.000 description 3
- VTXFLUJNMHWAAT-UHFFFAOYSA-N alternoside VII Natural products CC1(C)CC(O)C2(CO)C(O)CC3(C)C(=CCC4C5(C)CCC(OC6OC(C(O)C(OC7OC(CO)C(O)C(O)C7O)C6O)C(=O)O)C(C)(C)C5CCC34C)C2C1 VTXFLUJNMHWAAT-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- OILHVNROWDFZDW-UHFFFAOYSA-N prosapogenin Natural products CC1(C)CCC2(C(O)CC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6O)C(C)(C=O)C5CCC34C)C2C1)C(=O)O OILHVNROWDFZDW-UHFFFAOYSA-N 0.000 description 3
- IAGSHEHQJJTLLR-UHFFFAOYSA-N sapindoside B Natural products OC1C(C)OC(OC2C(OCC(O)C2O)OC2C(C3C(C4C(C5(CCC6(CCC(C)(C)CC6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)CO)C(O)C1OC1OCC(O)C(O)C1O IAGSHEHQJJTLLR-UHFFFAOYSA-N 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 206010043268 Tension Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11691079A JPS5640612A (en) | 1979-09-12 | 1979-09-12 | Agent for recovering from stress symptom complicated by automatic imbalance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11691079A JPS5640612A (en) | 1979-09-12 | 1979-09-12 | Agent for recovering from stress symptom complicated by automatic imbalance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5640612A JPS5640612A (en) | 1981-04-16 |
| JPS621372B2 true JPS621372B2 (enExample) | 1987-01-13 |
Family
ID=14698665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11691079A Granted JPS5640612A (en) | 1979-09-12 | 1979-09-12 | Agent for recovering from stress symptom complicated by automatic imbalance |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5640612A (enExample) |
-
1979
- 1979-09-12 JP JP11691079A patent/JPS5640612A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5640612A (en) | 1981-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spaulding | Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema) | |
| DE69931640T2 (de) | Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen | |
| Wilmer et al. | 5-hydroxytryptamine-3 receptors are involved in the initiation of gastric phase-3 motor activity in humans | |
| Bolton et al. | The effects of the anti-glucocorticoid RU 38486 on steroid-mediated suppression of experimental allergic encephalomyelitis (EAE) in the Lewis rat | |
| JPS58134031A (ja) | 多発性硬化症処置におけるジヒドロシクロスポリンｄ | |
| Merle et al. | Effect of melatonin on motility pattern of small intestine in rats and its inhibition by melatonin receptor antagonist S 22153 | |
| JPS621372B2 (enExample) | ||
| JP2872809B2 (ja) | モノシアロガングリオシドｇｍ▲下１▼またはその誘導体を含有する，パーキンソン病の治療に適する医薬組成物 | |
| JPH0121132B2 (enExample) | ||
| AU2019229892A1 (en) | Treatment of demyelinating diseases | |
| PT2877192T (pt) | Composições para o tratamento de fadiga relacionada com o cancro | |
| Laursen et al. | Effects of enprofylline and theophylline on exercise‐induced asthma | |
| Alergant | Treatment of gonorrhoea with amoxycillin | |
| Guerrero-Lindner et al. | Effect of motilin on gastrointestinal myoelectric activity in conscious rabbits | |
| RU2002115814A (ru) | Лечение системной красной волчанки с помощью дегидроэпиандростерона | |
| JP2627914B2 (ja) | プロスタグランジン類の選択的作用増強剤 | |
| IT8248556A1 (it) | Nuova applicazione terapeutica della n-ammidino-2-2,6-diclorofenil acetammide | |
| JPS5933221A (ja) | 心因性性行動障害回復剤 | |
| Tabachnick | Myasthenia gravis: consideration of recent advances and influence of pregnancy: report of case | |
| DE3525388C2 (enExample) | ||
| SERGENT et al. | Treatment of central nervous system lupus erythematosus | |
| US3483294A (en) | 1,1-diethyl-2-methyl - 3 - diphenylmethylenepyrrolidinium halide compositions and therapy | |
| CN110833553A (zh) | 吡唑并嘧啶衍生物在治疗Arthus反应的用途 | |
| DE2131626A1 (de) | 3,4,5-Dialkoxy-hydroxybenzoylaminoalkancarbonsaeuren und ihre Salze sowie Arzneipraeparate | |
| JPH05246857A (ja) | 痴呆症治療剤 |